Europe's drug regulator said on Wednesday an inspection of Indian generic drugmaker Ranbaxy Laboratories Ltd's Dewas plant in India is planned for June, amid concerns about its production processes after a spate of regulatory sanctions. Ranbaxy, which owner Japan's Daiichi Sankyo Ltd agreed to sell it to India's Sun Pharmaceutical Industries Ltd for $3.2 billion on Monday, suspended production at the Dewas plant in February to examine processes. The company's voluntary suspension at Dewas and another plant in Toansa in the northern Punjab state in February, came after a spate of sanctions against it by the U.S. Food and Drug Administration (FDA) due to poor manufacturing processes. via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment